Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273.

View in: PubMed

subject areas

Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Disease-Free Survival
Double-Blind Method
Female
Humans
Lung Neoplasms
Male
Mesothelioma
Middle Aged
Response Evaluation Criteria in Solid Tumors
Survival Rate
Treatment Outcome

authors with profiles

Hedy Kindler